Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at politicsandmyportfolio.com, will continue to monitor these healthtech companies to see if the momentum continues. PoliticsAndMyPortfolio.com is looking into these tickers DAWN, MTDR, AVY, CMC, MNST, RTX and more..
Recent AMAM Stock Price: $11.54
Summary: Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Yuan Zhi analyst at B.Riley Financial reiterates coverage on Ambrx Biopharma (AMAM) stock in the energy sector with a Buy rating and has set AMAM's stock price target at $26.
TipRanks.com reports that Ambrx Biopharma currently has 4 analysts offering 12-month price targets on AMAM and the consensus is a Strong Buy rating with an average stock price target of $22.25. The most recent AMAM stock price we have is $11.54 and we are not making any AMAM forecasts at this time.
In addition, TradingView issued a buy rating for AMAM over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AMAM. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AMAM, please click here >>
ACELYRIN, INC., SLRN
Recent SLRN Stock Price: $6.72
Summary: Acelyrin Inc. is a clinical biopharma company. It focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep. Acelyrin Inc. is based in Agoura Hills, California.
Yasmeen Rahimi analyst at Piper Sandler reiterates coverage on ACELYRIN, INC. (SLRN) stock in the energy sector with a Buy rating and has set SLRN's stock price target at $68.
TipRanks.com reports that ACELYRIN, INC. currently has 4 analysts offering 12-month price targets on SLRN and the consensus is a Strong Buy rating with an average stock price target of $30.75. The most recent SLRN stock price we have is $6.72 and we are not making any SLRN forecasts at this time.
In addition, TradingView issued a sell rating for SLRN over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SLRN. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SLRN, please click here >>
Arrowhead Pharmaceuticals, ARWR
Recent ARWR Stock Price: $21.20
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
David Lebovitz analyst at Citi reiterates coverage on Arrowhead Pharmaceuticals (ARWR) stock in the energy sector with a Hold rating and has set ARWR's stock price target at $33.
TipRanks.com reports that Arrowhead Pharmaceuticals currently has 4 analysts offering 12-month price targets on ARWR and the consensus is a Strong Buy rating with an average stock price target of $58.25. The most recent ARWR stock price we have is $21.20 and we are not making any ARWR forecasts at this time.
In addition, TradingView issued a Strong sell rating for ARWR over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ARWR, please click here >>
ImmunoGen, IMGN
Recent IMGN Stock Price: $29.35
Summary: ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla and in development programs of its partners Bayer, Biotest, CytomX, Novartis, Sanofi, Roche, Takeda, Debiopharm & Jazz Pharmaceuticals.'Among ImmunoGen's wholly owned candidates, mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha, is being developed as a single-agent therapy for platinum-resistant ovarian cancer and in combination regimens for both platinum-resistant and platinum-sensitive disease. The candidate is also being developed in combination with other cancer drugs in a mid-stage study.'Pivekimab sunirine is currently under evaluation in early- to mid-stage studies for treatment of patients with acute myeloid leukemia & other CD123-positive hematological malignancies.
Michael Schmidt analyst at Guggenheim reiterates coverage on ImmunoGen (IMGN) stock in the energy sector with a Hold rating and has set IMGN's stock price target at $31.
TipRanks.com reports that ImmunoGen currently has 3 analysts offering 12-month price targets on IMGN and the consensus is a Hold rating with an average stock price target of $31.00. The most recent IMGN stock price we have is $29.35 and we are not making any IMGN forecasts at this time.
In addition, TradingView issued a Strong buy rating for IMGN over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IMGN. politicsandmyportfolio.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IMGN, please click here >>
The editors at politicsandmyportfolio.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
PoliticsAndMyPortfolio.com keeps our subscribers informed of breaking news, reports, stock news or information that can have a positive or negative impact on their portfolio. We look at world events, political activity and the movement of stocks, bonds, metals, commodities and more to provide investors with timely information. Join thousands of investors who already signed up for our free subscription to PoliticsAndMyPortfolio.com.
==============================================================================
